ble litt rotete oppsatt: ligger her på side 10:
Denne da
Skal i helga sette opp hva eg tipper på. Men eg kan hinte om at Surveillance har eg ikkje trua på i år.
3 Likes
Ser bort fra Surveillance, ikkje interessant enda. Flexscop blir sannsynligvis vist frem 18 til 21 mai. http://www.aua2018.org/ Tidligst i Q4 kan vi forvente noe særlig salg fra Surveillance. Dette tar tid.
TURB US
Q1-2017 solgte vi 1276 stk, som var opp 22% Q til Q.
Fra 1.Jan var refusjon på plass, noe som bør starte ein økning av salg men TTT. (Medicare)
16.02 Fekk vi FDA godkjenning for flexiscope og gjentatt behandling uten restriksjon. Gjeld også TURB slik at vi ikkje lenger har 90 dager restriksjon. Siden vi fekk dette så seint i kvartalet har det nok ikkje før til noe ekstra salg.
I Q1 tipper eg vi har solgt 1720 stk i US. Det skal bli noe slikt som 13,5 NOKm. Opp ca 35%
Resten av verden blir vel som før. Spennande å sjå kva skjer med Ibsen.
Nordic - 13
US ------ 13,5
Partners 16
Total = 42,5
Edit
Så glemte eg at “NARROW-BAND IMAGING” mistet refusjon fra 01.01.18. Med litt tid vil nok dette også øke salge.
3 Likes
eg er redd du treffer bra sulzrox, 1700-2000 solgt , selv om eg håper på mer.
Mange som står på utsiden har nok selskapet på «radaren».
For min egen del har planen hele tiden vært å kjøpe etter fremleggelsen av Q1 (og før Q2). Grunnen er som du påpeker at TTT, og at noen kommer til å bli skuffet over salget i Q1.
Har du noen estimater for Q2 også?
1 Like
Blir veldig spennende å se effekten av refusjonen. Photocure økte guidingen fra 15 usd i 2020 til 25 usd i 2020 etter at de fikk refusjon.
Det tror jeg også mr. Oncoinvest.
Om Photocure viser på q1 at de har klart å trappe opp salget, så er det nok mange som får det travelt med å komme seg inn😊
14/05-2018 09:58:10: (PHO) Photocure to Present New Data on Cysview® at the 2018 American Urological Association Annual Meetin
Oslo, Norway, May 14th, 2018: Photocure ASA (PHO:OSE) announced today that
Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in
Booth 1825, during the American Urological Association Meeting (AUA 2018) in San
Francisco, CA.
New data on Cysview will be presented (see details below): in at least three
posters, of which two are on registry studies using real world longitudinal
data, a plenary session on Patient Reported Outcomes and during the Bladder
Cancer Surgical Technique session Dr. James McKiernan will present on “Enhanced
Cystoscopy: BLC - TURBT + Surveillance Video”. Earlier this year BLC with
Cysview was approved by the FDA for use in surveillance cystoscopy (in addition
to the already existing approval for TURBT’s (Trans Urethral Resection of the
Bladder)). “I have been using BLC with Cysview for both TURBT’s and
surveillance. I am looking forward to sharing my experience. Using these new
techniques more broadly should result in improved patient outcomes,” said Dr.
James McKiernan, John K Lattimer Professor and Chairman of Urology at Columbia
University and Urologist-in-Chief New York Presbyterian Hospital New York.
Photocure is also unveiling the company’s strategic focus, exhibiting as The
Bladder Cancer Company. “In this, the Bladder Cancer Awareness month, we are
excited to announce our continued focus on bladder cancer and look forward to
working with the bladder cancer community to increase awareness of Bladder
Cancer and our breakthrough technology, BLC with Cysview,” says Kjetil Hestdal,
MD, PhD, President and CEO, Photocure ASA.
Key Activities featuring Cysview during the meeting include:
May 18, 2018 (FRIDAY) 9:30 AM to 11:30AM - Location: MCC WEST, 3006
- Blue Light Cystoscopy Improves Detection Rates: Updated Results From A
Prospective Multicenter Registry - How is outpatient blue light cystoscopy used in clinical routine? First
results from the Nordic registry - The impact of Blue Light Cystoscopy on response of induction BCG in patients
with high-grade non-muscle invasive bladder cancer
May 19, 2018 (SATURDAY) - 4:33 PM to 4:42 PM - Location: MCC South, 208 - Assessment of Blue Light Flexible Cystoscopy with Cysview on Patient Reported
Outcomes- by Dr. Angela Smith, University of North Carolina
May 20, 2018 (SUNDAY) 7:00 AM to 9:00AM - Location: MCC WEST, 2005 - Blue light in combination with Cysview Leads to Bladder Cancer Cell Death in
an in vitro Mode
2:00 PM to 2:45 PM - MCC SOUTH, Esplanade (Plenary Session) - Surgical Techniques: Tips & Tricks: Bladder Cancer: Moderator: Dr. Kristen
Scarpato - Vanderbilt University with other Panel Members: Dr. Joe Liao - VA
Palo Alto and Dr. Bernie Bochner including: Dr. James McKiernan, New York
Presbyterian, Columbia University, who will present on Enhanced Cystoscopy - BLC - TURBT + Surveillance Video plus moderated presentation
May 17 and 18 (THURSDAY and FRIDAY), Photocure will be exhibiting at the AUA
Office Practice Management Conference - Location: MCC North, 22
3 Likes
Dette er jo virkelig lovende 
2 Likes
Nei. Vi får ta Q1 først.
Det er ansatt mange nye selgere og dei forsatt ansetter flere. Disse skal læres opp og så skal dei bli kjent med systemer og diverse. Hvor lang tid dette tar veit eg ikkje men eit halv år går fort.
Q1 kan fort overraske på opp siden. Håper på at kursen ikkje skal under 27 igjen. Teknisk ser det greit ut.
Her er link til studien @Longtrader skrev om.
Dette ligger veldig langt frem men viser hvor bra Cysview er.
https://www.jurology.com/article/S0022-5347(18)41014-2/fulltext
Der kan dere også søke på Cysview og får opp litt forskjellig.
2 Likes
Som Nano-aksjonær har jeg tålmodighet nok. Tok 3743 stk i dag. Venter med resten til etter Q1.
1 Like
16/05-2018 08:30:00: (PHO) Photocure Announces Blue Light Cystoscopy with Cysview® now available for surveillance of bladder cance
Dette blir bedre og bedre, nesten så en gleder seg til åpning 
4 Likes
Dette er det endelige resultatet av mange års målrettet jobbing for Photocure, så vi kan unne oss å poste hele pressemeldingen.
Store gratulasjoner til hele teamet!
PHO: PHOTOCURE ANNOUNCES BLUE LIGHT CYSTOSCOPY WITH CYSVIEW NOW AVAILABLE FOR SURVEILLANCE OF BLADDER CANCE
08:30
Oslo, Norway, Photocure ASA (OSE: PHO), May 16, 2018, announced today the launch
of Blue Light Cystoscopy (BLC™) with Cysview for a new indication of
surveillance cystoscopy of bladder cancer.
The new FDA approved indication was a result of a large Phase 3 study using blue
light rigid and flexible cystoscopes from KARL STORZ Endoscopy of America Inc.,
which showed that BLC with Cysview significantly (p0.0001) improves detection
of patients with recurrent bladder cancer. Click here for the Prescribing
Information.
We are pleased that we have commenced the first commercial sale of Cysview for
surveillance cystoscopy. This launch into the flexible cystoscopy segment is an
important milestone for patients with bladder cancer and the urology community.
The availability of Blue Light Cystoscopy with Cysview, for rigid and flexible
cystoscopy means that Cysview can now be used for both Bladder Cancer surgery
and follow-up cystoscopy, allowing physicians to detect patients with the
disease earlier and manage it more appropriately, says Kjetil Hestdal, MD, PhD,
President and CEO, Photocure ASA. I would like to thank all the investigators,
our partner KARL STORZ Endoscopy of America Inc. and the patients who made the
approval of this new indication possible.
Both companies are exhibiting at the 2018 American Urological Association Annual
meeting, in San Francisco, May 18 to 21, Photocure on booth 1825.
About Bladder Cancer
Bladder cancer is the fifth most commonly diagnosed cancer in the US and is the
fourth most common cancer found in men in the US1, 2, 3. It is estimated that in
2018 there will be 81,190 new cases of bladder cancer will occur along with
17,240 deaths due to bladder cancer. Risk factors for bladder cancer include
advancing age, cigarette smoking, occupational exposure to dyes, tar, rubber and
solvent, chronic bladder irritation and infections, and prior diagnosis of
bladder cancer. Bladder cancer is one of the most expensive cancers to manage,
accounting for approximately $3.7 billion in direct costs each year.4,5
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall.2 NMIBC is still in the inner layer of cells. These
cancers are the most common (75%) of all BC cases and include the subtypes Ta,
carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer has grown into
deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and
T4, are more likely to spread and are harder to treat.2
About Hexvix/Cysview
Hexvix/Cysview (hexaminolevulinate hydro-chloride), is an optical imaging
agent used in the diagnosis and management of non-muscle-invasive bladder
cancer. It is designed to selectively target malignant cells in the bladder and
induce fluorescence during a cystoscopic procedure using a blue light enabled
cystoscope. Using Cysview as an adjunct to standard white light cystoscopy
enables the urologist to better detect and remove lesions, leading to a reduced
risk of recurrence.
Hexvix is the tradename in Europe, Cysview in US and Canada. Hexvix is
marketed and sold by Photocure in the Nordic countries and in the US with the
trade name Cysview. Photocure has a strategic partnership with Ipsen for the
commercialization of Hexvix in Europe, excluding the Nordic region. Please refer
to http://bit.ly/PHO-Partnering for further information on our commercial
partners.
About Photocure ASA
Photocure, The Bladder Cancer Company, delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in
Princeton, New Jersey. For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com
About KARL STORZ Endoscopy-America, Inc.
KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ GmbH & Co. KG,
an international leader for more than 70 years in reusable endoscope technology,
encompassing all endoscopic specialties. Based in Tuttlingen, Germany, KARL
STORZ GmbH & Co. KG is a family-owned company that designs, engineers,
manufactures, and markets all its products with an emphasis on visionary design,
precision craftsmanship and clinical effectiveness. For more information, call
(800) 421-0837 or visit the companys website at www.karlstorz.com.
For more information, please contact:
Company contacts:
Kjetil Hestdal
President and CEO
Tel: +47 913 19 535
Email: [email protected]
US President:
Ambaw Bellete
President
Photocure Inc.,
Tel: + 1-609-759-6515
Email: [email protected]
Media Relations:
Amanda Hudson
MCS Healthcare Public Relations
Tel: +1 908 234 9900
Email: [email protected]
References:
- SEER Cancer Statistics Factsheets: Bladder Cancer. National Cancer Institute.
Bethesda, MD. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed April - Bladder Cancer. American Cancer Society.
http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf.
Accessed April 2018. - Hall M, Chang S, Dalbagni G et al. Guideline for the Management of Nonmuscle
Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. J Urol. 2007
Source Url: http://www.newsweb.no/index.jsp?messageId=451554
© Oslo Børs
5 Likes
Lik og retweet!
5 Likes
Her ser ein hvordan Cysview blir brukt i praksis. Som ein ser treng ein nok litt opplæring og praksis for å bli flink.
1 Like
Omsider litt bevegelse i kursen på PHO
Fint driv i aksjen i dag. Har tikket sakte, men sikkert oppover gjennom hele dagen. På et volum godt over normalen.
Starten på en lang opptur, på et fremtidig utbytte selskap håper eg.
1 Like
1 Like